error fb Gplus IN twitter down-arrow Email Phone Check-Mark padlock circle_arrow minus plus play_btn close Clipboard_Icon Shopping-Cart_Icon Speech_Bubble_Icon Stethoscope_Icon pharmacists menu left-arrow right-arrow facebook search cart

On April 1, 2020, FDA notified Dexcom that it is exercising its enforcement discretion and will not object to the use of Dexcom’s CGM systems for the treatment of patients in hospital settings and other healthcare facilities to support COVID-19 healthcare-related efforts during the current pandemic, though this does not expand Dexcom’s current authorized indications for use for its home use product.


Extending use of the Dexcom CGM systems to hospitalized patients during the COVID-19 emergency in order to allow hospital staff to remotely monitor glucose in patients may reduce provider/patient interaction, limiting viral exposure by hospital staff and preserving personal protective equipment.


However, this information should be reviewed carefully by healthcare professionals before using the Dexcom CGM systems in hospital settings: click here


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.